相关实验视频

Updated: May 6, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

早期辅助血压素启动对败血症休克患者的影响:一个向试验仿真试验

Kyle C White^1,2,3, Rahul Costa-Pinto^4,5, Sebastiaan Blank⁶

¹Department of Intensive Care Unit, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, QLD, 4102, Australia. kyle.white@health.qld.gov.au.

Critical care (London, England)

|May 12, 2025

概括

在败血性休克患者中早期使用血管压素可以将重症监护室死亡率降低5%. 这一发现在较低的上腺素剂量时最为明显,这表明潜在的益处超出了当前的指导方针.

科学领域:

关键护理医学关键护理医学
药理学药理学是指药理学的学科.
败血症研究败血症研究

背景情况:

在败血症休克中开始使用血管压素的最佳时间尚不清楚.
早期输血压素的使用可能会改善性休克患者的治疗结果.

研究的目的:

评估早期 (在6小时内) 辅助血压素启动对30天重症监护室 (ICU) 感染性休克患者死亡率的影响.
探索随着时间的推移,血管压素使用和患者特征的子组效应和趋势.

主要方法:

多中心目标试验模拟使用参数g-formula.
纳入标准:在ICU入院6小时内诊断出败血症休克.
主要结局:30天ICU死亡率;次要结局包括延迟的血管压素影响和北上腺素等效剂量 (NED) 影响.

主要成果:

整体30天ICU死亡率为19.34% (没有血管压素) 与18.45% (早期血管压素),RR为0.95 (95%CI,0.93至0.98).
早期的血管压素在低于推的北上腺素剂量时显示出显著的益处.
血管压素的使用量从2015年的35.2%增加到2021年的45.1%,在开始时NED和SOFA得分下降.

结论:

在败血症休克患者的早期血管压素给药显示出死亡率的好处.
这些发现支持设计前性随机对照试验,用于早期辅助压素的使用.

关键词:

关键的护理关键的护理血压下降血压下降血压下降败血症这是一种败血症.冲击和冲击是一个很大的问题.血管扩张是一种血管扩张.血管压力中的压力.

更多相关视频

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...